1. Home
  2. MESO vs IAS Comparison

MESO vs IAS Comparison

Compare MESO & IAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • IAS
  • Stock Information
  • Founded
  • MESO 2004
  • IAS 2009
  • Country
  • MESO Australia
  • IAS United States
  • Employees
  • MESO N/A
  • IAS N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • IAS Computer Software: Programming Data Processing
  • Sector
  • MESO Health Care
  • IAS Technology
  • Exchange
  • MESO Nasdaq
  • IAS Nasdaq
  • Market Cap
  • MESO 2.0B
  • IAS 1.8B
  • IPO Year
  • MESO N/A
  • IAS 2021
  • Fundamental
  • Price
  • MESO $18.04
  • IAS $10.15
  • Analyst Decision
  • MESO Buy
  • IAS Buy
  • Analyst Count
  • MESO 4
  • IAS 11
  • Target Price
  • MESO $13.50
  • IAS $14.80
  • AVG Volume (30 Days)
  • MESO 828.2K
  • IAS 768.9K
  • Earning Date
  • MESO 02-28-2025
  • IAS 02-25-2025
  • Dividend Yield
  • MESO N/A
  • IAS N/A
  • EPS Growth
  • MESO N/A
  • IAS 258.32
  • EPS
  • MESO N/A
  • IAS 0.20
  • Revenue
  • MESO $5,902,000.00
  • IAS $511,358,000.00
  • Revenue This Year
  • MESO $65.99
  • IAS $11.97
  • Revenue Next Year
  • MESO $425.77
  • IAS $11.96
  • P/E Ratio
  • MESO N/A
  • IAS $51.86
  • Revenue Growth
  • MESO N/A
  • IAS 11.77
  • 52 Week Low
  • MESO $1.72
  • IAS $7.98
  • 52 Week High
  • MESO $22.00
  • IAS $17.53
  • Technical
  • Relative Strength Index (RSI)
  • MESO 59.20
  • IAS 46.51
  • Support Level
  • MESO $15.92
  • IAS $9.86
  • Resistance Level
  • MESO $17.67
  • IAS $10.15
  • Average True Range (ATR)
  • MESO 1.38
  • IAS 0.32
  • MACD
  • MESO -0.37
  • IAS 0.02
  • Stochastic Oscillator
  • MESO 37.14
  • IAS 43.72

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About IAS Integral Ad Science Holding Corp.

Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.

Share on Social Networks: